Veppanu Tablet, Film Coated
NDC Package 71332-007-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Veppanu (vepdegestrant) tablets is vEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. This formulation utilizes a tablet, film coated delivery system. Marketed by Rigel Pharmaceuticals, Inc., this product is identified by NDC 71332-007 and is authorized under FDA application NDA219835.

Identification & Billing

NDC Package Code
71332-007-30
Package Description
30 TABLET, FILM COATED in 1 BOTTLE
Product Code
71332-007
11-Digit Billing Format
71332000730
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Veppanu
Non-Proprietary Name
Vepdegestrant
Substance Name
Vepdegestrant
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
VEPDEGESTRANT 100 mg/1
Usage Information
VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

Regulatory & Marketing

Labeler Name
Rigel Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA219835
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-16-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71332-007-30 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Veppanu, a human prescription drug labeled by Rigel Pharmaceuticals, Inc.. This tablet, film coated is formulated for oral use and contains vepdegestrant as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Rigel Pharmaceuticals, Inc. on June 16, 2026. The current certification is valid through December 31, 2027.

How is this Rigel Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71332000730. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71332-007-30
11-Digit CMS (5-4-2)
71332-0007-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.